Guardant Health announces European approval for Guardant360 CDx

GH•2026-10-08

Guardant Health said Guardant360 CDx was approved in Europe as a companion diagnostic for AstraZeneca’s Etcamah (camizestrant) in advanced ER-positive breast cancer.

1. European approval

Guardant Health announced that Guardant360 CDx was approved in Europe as a companion diagnostic for AstraZeneca’s Etcamah (camizestrant) in advanced ER-positive breast cancer.

Guardant Health announces European approval for Guardant360 CDx

1. European approval

Related News

CoreWeave CFO Nitin Agrawal sells $266 in Class A shares

Alerts on Bitdeer AI's data center services agreement withdrawn

Hurricane Isaias strengthens as US Gulf Coast prepares for landfall

Ci&T director and 10% owner Fernando Matt Borges Martins reports $49,369 share purchase

Patricia E. Lopez to retire from Domino's Pizza board effective October 7, 2026